- Home
- OLO vs ARDX Comparison
OLO vs ARDX Comparison
Compare OLO & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OLO
- ARDX
- Stock Information
- Founded
- OLO 2005
- ARDX 2007
- Country
- OLO United States
- ARDX United States
- Employees
- OLO N/A
- ARDX N/A
- Industry
- OLO Major Banks
- ARDX Biotechnology: Pharmaceutical Preparations
- Sector
- OLO Finance
- ARDX Health Care
- Exchange
- OLO Nasdaq
- ARDX Nasdaq
- Market Cap
- OLO 1.2B
- ARDX 1.2B
- IPO Year
- OLO 2021
- ARDX 2014
- Fundamental
- Price
- OLO $7.23
- ARDX $5.52
- Analyst Decision
- OLO Buy
- ARDX Buy
- Analyst Count
- OLO 3
- ARDX 7
- Target Price
- OLO $8.67
- ARDX $9.42
- AVG Volume (30 Days)
- OLO 1.1M
- ARDX 4.8M
- Earning Date
- OLO 02-19-2025
- ARDX 02-20-2025
- Dividend Yield
- OLO N/A
- ARDX N/A
- EPS Growth
- OLO N/A
- ARDX N/A
- EPS
- OLO N/A
- ARDX N/A
- Revenue
- OLO $271,872,000.00
- ARDX $251,849,000.00
- Revenue This Year
- OLO $24.59
- ARDX $169.09
- Revenue Next Year
- OLO $15.65
- ARDX $15.06
- P/E Ratio
- OLO N/A
- ARDX N/A
- Revenue Growth
- OLO 26.41
- ARDX 87.57
- 52 Week Low
- OLO $4.20
- ARDX $4.32
- 52 Week High
- OLO $8.35
- ARDX $10.13
- Technical
- Relative Strength Index (RSI)
- OLO 46.70
- ARDX 55.33
- Support Level
- OLO $7.08
- ARDX $5.15
- Resistance Level
- OLO $7.60
- ARDX $5.61
- Average True Range (ATR)
- OLO 0.28
- ARDX 0.31
- MACD
- OLO -0.04
- ARDX 0.01
- Stochastic Oscillator
- OLO 31.55
- ARDX 70.53
About OLO Olo Inc.
Olo Inc is an open Software as a Service platform for restaurants. Its platform powers restaurant brands' on-demand digital commerce operations, enabling digital ordering, delivery, front-of-house management, and payments, while further strengthening and enhancing restaurants' direct guest relationships. The company generates revenue from providing its customers access to its platform.
About ARDX Ardelyx Inc.
Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of innovative, first-in-class medicines that meet significant unmet medical needs. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.